Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Beijing Tongren Hospital
Updated on 25 January 2021
renal function


The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with decitabine in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients


Previous study has confirmed the efficacy of anti-PD-1 antibodies (including pembrolizumab or sintilimab). However, the CR rate of PD-1 antibody monotherapy is too low. Previous studies have demonstrated that decitabine may activate the T cells and enhance the efficacy of PD-1 antibodies in Hodgkin Lymphoma. Thus, the investigators aim to evaluate the efficacy and safety of sintilimab in combination with decitabine in the treatment of NK/T cell lymphoma.

Condition Angiocentric T-cell lymphoma, T-Cell Lymphoma, extranodal nk/t-cell lymphoma
Treatment Decitabine, Sintilimab
Clinical Study IdentifierNCT04279379
SponsorBeijing Tongren Hospital
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Histopathology and immunohistochemistry confirmed diagnosis of NK/Tcell
lymphoma according to WHO 2016 criteria
refractory or relapsed after initial remission, or stage III-IV de novo patients
PET/CT or CT/MRI with at least one objectively evaluable lesion
General status ECOG score 0-3 points
The laboratory test within 1 week before enrollment meets the following conditions: Blood routine: Hb>80g/L, PLT>5010e9/L. Liver function: ALT, AST, TBIL 2 times the upper limit of normal. Renal function: Cr is normal. Cardiac function: LVEF50%, ECG does not suggest any acute myocardial infarction, arrhythmia or atrioventricular conduction above I Blocking
Sign the informed consent form

Exclusion Criteria

Active infection requires ICU treatment. Concomitant HIV infection or active
infection with HBV, HCV. Patients who are infected with HBV but not active
hepatitis at the same time are notexcluded
Significant organ dysfunction Pregnant and lactating women. Had a history of
autoimmune diseases, and disease was active in the last 6 months
Those who were known to be allergic to drugs in the study regimen. Patients
with other tumors who require surgery or chemotherapy within 6 months
Other experimental drugs are being used
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note